Volume 18, Issue 11, Pages 1432-1441 (November 2011) Bisubstrate Adenylation Inhibitors of Biotin Protein Ligase from Mycobacterium tuberculosis  Benjamin P. Duckworth, Todd W. Geders, Divya Tiwari, Helena I. Boshoff, Paul A. Sibbald, Clifton E. Barry, Dirk Schnappinger, Barry C. Finzel, Courtney C. Aldrich  Chemistry & Biology  Volume 18, Issue 11, Pages 1432-1441 (November 2011) DOI: 10.1016/j.chembiol.2011.08.013 Copyright © 2011 Elsevier Ltd Terms and Conditions

Chemistry & Biology 2011 18, 1432-1441DOI: (10. 1016/j. chembiol. 2011 Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 1 Enzyme Reaction Catalyzed by BPL (A) First half-reaction to form biotin adenylate. (B) Second half-reaction involving transfer of biotin to acetyl CoA carboxylases. (C) Bisubstrate inhibitors of BPL and degradation products of 5. See also Figure S1. Chemistry & Biology 2011 18, 1432-1441DOI: (10.1016/j.chembiol.2011.08.013) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 2 In Vitro Analysis and Mechanism of Action Studies of Bio-AMS Inhibitor (A) Dose-response of MtBPL with inhibitor Bio-AMS. vi and v0 are velocities of inhibitor and DMSO treated samples, respectively. (B) Competitive ITC trace of a solution of Bio-AMS (200 μM) in 10 mM Tris (pH 7.5), 200 mM KCl, and 2.5 mM MgCl2 titrated into a solution of MtBPL (20 μM) and biotin (150 μM) in the same buffer. (C) Western blot analysis of biotinylated protein levels in lysates from Mtb H37Rv cells treated with varying concentrations of Bio-AMS. Lane M: biotinylated molecular weight marker; Lane 1, DMSO-treated MTB cells; Lane 2, Mtb cells treated with 0.1 μM Bio-AMS; Lane 3: Mtb cells treated with 1.0 μM Bio-AMS. The dashed box corresponds to the section of the gel that was excised for trypsin digestion and LC-MS/MS analysis. (D) Normalized band intensities of bands in lanes 1–3 from (C). See also Figure S2 and Table S2. Chemistry & Biology 2011 18, 1432-1441DOI: (10.1016/j.chembiol.2011.08.013) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 3 Impact of MtBPL Expression on Drug Susceptibility of M. smegmatis and Mtb (A–D) In (A) and (C), 10 μg of total protein extracts of the indicated strains were used to measure MtBPL expression by western blotting. Enolase (lower panels) served as the loading control. (B) and (D) show susceptibility of M. smegmatis (MtBPL-H [black], MtBPL-M [blue], and MtBPL-L [red]) and Mtb (MtBPL-H [black], MtBPL-M [blue], and wt [red]) to BioAMS. Normalized growth was calculated as OD580 at the indicated drug concentration divided by OD580 without drug. Error bars represent SEMs of 4 to 8 measurements. See also Figures S3–S5. Chemistry & Biology 2011 18, 1432-1441DOI: (10.1016/j.chembiol.2011.08.013) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 4 Structure of Bio-AMS with MtBPL (A) The MtBPL binding site showing the loops undergoing the order-to-disorder transition (gray) upon binding of Bio-AMS (green carbons). Specific hydrogen bonds are shown in yellow dashes. Asn130 is omitted for clarity. (B) Schematic view of polar interactions between biotin (purple), acylsulfamide linker (red/green), ribose (orange), and adenosine (blue) portions of Bio-AMS and MtBPL. See also Figure S6 and Table S3. Chemistry & Biology 2011 18, 1432-1441DOI: (10.1016/j.chembiol.2011.08.013) Copyright © 2011 Elsevier Ltd Terms and Conditions